Search results for "Coagulant"
showing 10 items of 342 documents
Position paper on laboratory testing for patients on direct oral anticoagulants. A Consensus Document from the SISET, FCSA, SIBioC and SIPMeL
2018
Although direct oral anticoagulants (DOAC) do not require dose-adjustment on the basis of laboratory test results, the measurement of their anticoagulant effect is useful in special situations. This position paper issued by the Italian Scientific Societies that are mainly involved in the management of patients on DOAC is aimed at providing guidance to care-givers on which tests should be used and the situations in which testing is useful. The guidance is based on the data from the literature so far available and/or on consensus among experts.
Long Term Outcome after Application of the Angio-Seal Vascular Closure Device in Minipigs
2016
PLoS one 11(9), e0163878 (2016). doi:10.1371/journal.pone.0163878
Are Anticoagulants and Antiplatelet Agents Important in Thoracic Surgery?
2020
The management of antithrombotic drugs (antiplatelet and anticoagulant agents) is a common challenging issue in patients undergoing thoracic surgery. The procedure can require the temporary interruption of these drugs because of their associated haemorrhagic risk, therefore assuming a thrombotic risk also. The assessment of the balance between both risks gives us their optimal management.
Apical thrombus in a patient with takotsubo cardiomyopathy
2008
We report a case of apical thrombus formation among a group of 15 patients with takotsubo cardiomyopathy who were referred for a suspected acute coronary syndrome over a 2.5-year period. To the best of our knowledge, no data are available regarding the treatment of this syndrome. According to current literature and our reported experience, the use of anticoagulant therapy administered until complete resolution of wall motion abnormalities appears to be appropriate to treat apical thrombus formation and any possible subsequent embolism. © 2008 Italian Federation of Cardiology.
Heparin–polynitroxide derivatives: a platform for new diagnostic and therapeutic agents in cardiovascular disease?
2013
Vascular wall extracellular oxidative stress Cardiovascular disease (CVD; mainly atherosclerosis, hypertension and diabetes mellitus) remains a major cause of death in western society [1]. Despite substantial progress achieved, the diagnosis of CVD often comes too late, when the disease has already advanced to therapeutically incurable stages. The development of efficient diagnostic probes allowing early non-invasive diagnostics, as well as drugs which can prevent or reverse CVD and/or its complications (e.g., myocardium infarctus and stroke) are highly desired tasks of the modern cardiovascular medicinal chemistry.
2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism
2014
ACS : acute coronary syndrome AMPLIFY : Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-line Therapy aPTT : activated partial thromboplastin time b.i.d. : bis in diem (twice daily) b.p.m. : beats per minute BNP : brain natriuretic peptide BP : blood pressure CI : confidence interval CO : cardiac output COPD : chronic obstructive pulmonary disease CPG : Committee for Practice Guidelines CRNM : clinically relevant non-major CT : computed tomographic/tomogram CTEPH : chronic thromboembolic pulmonary hypertension CUS : compression venous ultrasonography DSA : digital subtraction angiography DVT : deep vein thrombosis ELISA : enzyme-linked immunosorben…
Real-World Data of Anticoagulant Treatment in Non-valvular Atrial Fibrillation
2022
AimsTo assess the impact of anticoagulant treatment on risk for stroke and all-cause mortality of patients with atrial fibrillation using real-world data (RWD).MethodsPatients with prevalent or incident atrial fibrillation were selected throughout a study period of 5 years. Stroke, transitory ischemic attack, hemorrhagic stroke, and all-cause mortality were identified in the claims of the electronic health records (EHRs). Subjects were classified according to the anticoagulant treatment in four groups: untreated, vitamin K antagonists (VKAs), New Oral Anticoagulants (NOACs), and antiplatelet (AP). Risk of events and protection with anticoagulant therapy were calculated by Cox proportional h…
Orālo antikoagulantu aprite SIA "Jēkabpils Vecpilsētas aptieka" laika periodā no 2017. līdz 2019. gadam
2020
Sirds išēmiskās slimības un insults ir viens no galvenajiem iemesliem mirstībai pasaulē. Šīs slimības pēdējos 15 gados ir bijušas galvenie nāves cēloņi visā pasaulē. Ir dažādas slimības, kad iesaka ārstēšanu ar antikoagulantiem. Biežākā no tām ir mirdzaritmija (MA) jeb priekškambaru (ātriju) fibrillācija (ĀF). Antikoagulantu lietošana dažādās vecuma grupās ir plaši izplatīta visā pasaulē. Eiropas ārstēšanas vadlīnijas mirdzaritmijas izraisīta insulta profilaksei neiesaka lietot antiagregantus, piemēram, aspirīnu, bet iesaka lietot antikoagulantus kā visefektīvākās zāles, jo tie var mazināt risku par divām trešdaļām vai pat vairāk. Bez antikoagulantu terapijas aptuveni 1 no 20 mirdzaritmijas…
Cancer‐associated venous thromboembolism: Treatment and prevention with rivaroxaban
2020
Abstract Cancer‐associated venous thromboembolism (VTE) is a frequent, potentially life‐threatening event that complicates cancer management. Anticoagulants are the cornerstone of therapy for the treatment and prevention of cancer‐associated thrombosis (CAT); factor Xa–inhibiting direct oral anticoagulants (DOACs; apixaban, edoxaban, and rivaroxaban), which have long been recommended for the treatment of VTE in patients without cancer, have been investigated in this setting. The first randomized comparisons of DOACs against low‐molecular‐weight heparin for the treatment of CAT indicated that DOACs are efficacious in this setting, with findings reflected in recent updates to published guidan…
Antithrombotic Therapy in Elderly Patients with Acute Coronary Syndromes
2022
The treatment of acute coronary syndrome (ACS) in elderly patients continues to be a challenge because of the characteS.G.B.ristics of this population and the lack of data and specific recommendations. This review summarizes the current evidence about critical points of oral antithrombotic therapy in elderly patients. To this end, we discuss the peculiarities and differences reported referring to dual antiplatelet therapy (DAPT) in ACS management in elderly patients and what might be the best option considering these population characteristics. Furthermore, we analyze antithrombotic strategies in patients with atrial fibrillation (AF), with a particular focus on those cases that also presen…